Expression of CDK13 Was Associated with Prognosis and Expression of HIF-1α and beclin1 in Breast Cancer Patients

References

• Winters S, Martin C, Murphy D, Shokar NK. Breast cancer epidemiology, prevention, and screening. Prog Mol Biol Transl Sci. 2017;151:1–32. doi:https://doi.org/10.1016/bs.pmbts.2017.07.002.
   Google Scholar
• Rojas K, Stuckey A. Breast cancer epidemiology and risk factors. Clin Obstet Gynecol. 2016;59(4):651–672. doi:https://doi.org/10.1097/GRF.0000000000000239.
   PubMed Web of Science ®Google Scholar
• Desantis C, Fedewa SA, Sauer AG, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin. 2016;66(1):31–42. doi:https://doi.org/10.3322/caac.21320.
   PubMed Web of Science ®Google Scholar
• Ito H, Matsuo K. Molecular epidemiology, and possible real-world applications in breast cancer. Breast Cancer. 2016;23(1):33–38. doi:https://doi.org/10.1007/s12282-015-0609-8.
   PubMed Web of Science ®Google Scholar
• Li T, Mello-Thoms C, Brennan PC. Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence. Breast Cancer Res Treat. 2016;159(3):395–406. doi:https://doi.org/10.1007/s10549-016-3947-0.
   PubMed Web of Science ®Google Scholar
• Zheng R, Zeng H, Zhang S, Chen T, Chen W. National estimates of cancer prevalence in China, 2011. Cancer Lett. 2016;370(1):33–38. doi:https://doi.org/10.1016/j.canlet.2015.10.003.
   PubMed Web of Science ®Google Scholar
• Fan L, Strasserweippl K, Li JJ. Breast cancer in China. Lancet Oncol. 2014;15(7):e279–89. doi:https://doi.org/10.1016/S1470-2045(13)70567-9.
   Google Scholar
• Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat. 1996;41(2):177–185. doi:https://doi.org/10.1007/BF01807163.
   PubMed Web of Science ®Google Scholar
• Aleskandarany MA, Soria D, Green AR, et al. Markers of progression in early-stage invasive breast cancer: a predictive immunohistochemical panel algorithm for distant recurrence risk stratification. Breast Cancer Res Treat. 2015;151(2):325–333. doi:https://doi.org/10.1007/s10549-015-3406-3.
   PubMed Web of Science ®Google Scholar
• Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha EJ, Sessler DI. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis. Anesthesiology. 2006;105(4):660–664. doi:https://doi.org/10.1097/00000542-200610000-00008.
   PubMed Web of Science ®Google Scholar
• Chen F, Chen J, Yang L, et al. Extracellular vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells. Nat Cell Biol. 2019;21(4):498–510. doi:https://doi.org/10.1038/s41556-019-0299-0.
   PubMed Web of Science ®Google Scholar
• Jin J, Qiu S, Wang P, et al. Cardamonin inhibits breast cancer growth by repressing HIF-1α-dependent metabolic reprogramming. J Exp Clin Cancer Res. 2019;38(1):1–16. doi:https://doi.org/10.1186/s13046-019-1351-4.
   PubMed Web of Science ®Google Scholar
• De Francesco EM, Maggiolini M, Musti AM. Crosstalk between Notch, HIF-1α and GPER in breast cancer EMT. IJMS. 2018;19(7):2011. doi:https://doi.org/10.3390/ijms19072011.
   Google Scholar
• De S, Das S, Sengupta S. Involvement of HuR in the serum starvation induced autophagy through regulation of Beclin1 in breast cancer cell-line, MCF-7. Cell Signal. 2019;61:78–85. doi:https://doi.org/10.1016/j.cellsig.2019.05.008.
   PubMed Web of Science ®Google Scholar
• Hamurcu Z, Delibaşı N, Nalbantoglu U, et al. FOXM1 plays a role in autophagy by transcriptionally regulating Beclin-1 and LC3 genes in human triple-negative breast cancer cells. J Mol Med (Berl). 2019;97(4):491–508. doi:https://doi.org/10.1007/s00109-019-01750-8.
   PubMed Web of Science ®Google Scholar
• Gu Y, Chen T, Li G, et al. Lower Beclin 1 downregulates HER2 expression to enhance tamoxifen sensitivity and predicts a favorable outcome for ER positive breast cancer. Oncotarget. 2017;8(32):52156–52177. doi:https://doi.org/10.18632/oncotarget.11044.
   PubMedGoogle Scholar
• Lin W, Yin C-Y, Yu Q, et al. Expression of glucose transporter-1, hypoxia inducible factor-1α and beclin-1 in head and neck cancer and their implication. Int J Clin Exp Pathol. 2018;11(7):3708–3717.
   PubMed Web of Science ®Google Scholar
• Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14(2):130–146. doi:https://doi.org/10.1038/nrd4504.
   PubMed Web of Science ®Google Scholar
• Whittaker SR, Mallinger A, Workman P, Clarke PA. Inhibitors of cyclin-dependent kinases as cancer therapeutics. Pharmacol Ther. 2017;173:83–105. doi:https://doi.org/10.1016/j.pharmthera.2017.02.008.
   PubMed Web of Science ®Google Scholar
• Chou J, Quigley DA, Robinson TM, Feng FY, Ashworth A. Transcription-associated cyclin-dependent kinases as targets and biomarkers for cancer therapy. Cancer Discov. 2020;10(3):351–370. doi:https://doi.org/10.1158/2159-8290.CD-19-0528.
   PubMed Web of Science ®Google Scholar
• Del Re M, Bertolini I, Crucitta S, et al. Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients. Breast Cancer Res Treat. 2019;178(1):57–62. doi:https://doi.org/10.1007/s10549-019-05365-y.
   PubMed Web of Science ®Google Scholar
• Zhang H, Pandey S, Travers M, et al. Targeting CDK9 reactivates epigenetically silenced genes in cancer. Cell. 2018;175(5):1244–1258. doi:https://doi.org/10.1016/j.cell.2018.09.051.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang Y, Lu L, Lu Y, Tang Q, Pu J. Insight into the molecular mechanism of LINC00152/miR-215/CDK13 axis in hepatocellular carcinoma progression. J Cell Biochem. 2019;120(11):18816–18825. doi:https://doi.org/10.1002/jcb.29197.
   PubMed Web of Science ®Google Scholar
• Kim J-Y, Lim JE, Jung HH, et al. Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort. Breast Cancer Res Treat. 2018;171(3):737–745. doi:https://doi.org/10.1007/s10549-018-4858-z.
   PubMed Web of Science ®Google Scholar
• Quereda V, Bayle S, Vena F, et al. Therapeutic targeting of CDK12/CDK13 in triple-negative breast cancer. Cancer Cell. 2019;36(5):545–558. doi:https://doi.org/10.1016/j.ccell.2019.09.004.
   PubMed Web of Science ®Google Scholar
• Kim H-E, Kim D-G, Lee KJ, et al. Frequent amplification of CENPF, GMNN and CDK13 genes in hepatocellular carcinomas. PloS One. 2012;7(8):e43223. doi:https://doi.org/10.1371/journal.pone.0043223.
   PubMed Web of Science ®Google Scholar
• Dong X, Chen G, Cai Z, et al. CDK13 RNA over-editing mediated by ADAR1 associates with poor prognosis of hepatocellular carcinoma patients. Cell Physiol Biochem. 2018;47(6):2602–2612. doi:https://doi.org/10.1159/000491656.
   PubMedGoogle Scholar
• Hamman K, Bradley M, Marineau J, et al. Targeting the transcriptional kinases CDK12 and CDK13 in breast and ovarian cancer. FASEB J. 2017;31:938–939.
   Web of Science ®Google Scholar
• Zeng M, Kwiatkowski NP, Zhang T, et al. Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13. Elife. 2018;7:e39030. doi:https://doi.org/10.7554/eLife.39030.
   PubMed Web of Science ®Google Scholar
• Osman NA, Abd El-Rehim DM, Kamal IM. Defective Beclin-1 and elevated hypoxia-inducible factor (HIF)-1α expression are closely linked to tumorigenesis, differentiation, and progression of hepatocellular carcinoma. Tumor Biol. 2015;36(6):4293–4299. doi:https://doi.org/10.1007/s13277-015-3068-0.
   PubMedGoogle Scholar
• Chen Y, Lu Y, Lu C, Zhang L. Beclin-1 expression is a predictor of clinical outcome in patients with esophageal squamous cell carcinoma and correlated to hypoxia-inducible factor (HIF)-1alpha expression. Pathol Oncol Res. 2009;15(3):487–493. doi:https://doi.org/10.1007/s12253-008-9143-8.
   PubMed Web of Science ®Google Scholar
• Dong M, Wan X-b, Yuan ZY, et al. Low expression of Beclin 1 and elevated expression of HIF-1α refine distant metastasis risk and predict poor prognosis of ER-positive, HER2-negative breast cancer. Med Oncol. 2013;30(1):355. doi:https://doi.org/10.1007/s12032-012-0355-0.
   PubMed Web of Science ®Google Scholar